Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement

Uroplasty, Inc. 

and Vision-Sciences, Inc.

shareholders have voted at the special meeting of each company's shareholders held today to approve the previously announced agreement and plan of merger between the two companies. "We are pleased with the outcome of today's special meetings, and I would like to thank both shareholder groups for approving the merger agreement," said Rob Kill, President and CEO of Uroplasty. "Our shareholders have endorsed a transformative combination that will form a new medical device company well positioned for growth and value creation for our stakeholders." Howard Zauberman, President and CEO of Vision-Sciences, commented, "Our shareholders have voted to maximize the market opportunity for the EndoSheath technology and growth of our combined company, and we look forward to accelerating growth as one company." Completion of the merger is expected to occur later this week subject to certain closing conditions.  Upon completion, the two companies will operate as Cogentix Medical, Inc. and trade on NASDAQ under the symbol CGNT. About UroplastyUroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for